We’re All In
Watch our video to learn about our approach to innovation and partnerships
Szukaj
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
A Unique Bond: human and animal health
At Boehringer Ingelheim we are dedicated to animal and human health. We celebrate the truly unique bonds between people and their pets.
Boehringer Ingelheim Academy
Find out more about our networking and educational initiative
A beginner’s guide to fighting off cat parasites
Prof. Donato Traversa explains the risk of multiparasitic infections and/or infestations in cats
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
PREVEXXION®: szczepionki nowej generacji przeciwko chorobie Mareka są już dostępne w Unii Europejskiej
PREVEXXION®: szczepionki nowej generacji przeciwko chorobie Mareka są już dostępne w Unii Europejskiej
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Biotherapeutics Discovery
We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Historia Boehringer Ingelheim w latach 1948-1990,
Historia Boehringer Ingelheim w latach 1948-1990, z kamieniami milowymi
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Historia (1885-1948): Nowatorskie początki
Historia Boehringer Ingelheim od rozpoczęcia działalności w 1885 roku do 1948 roku, z kamieniami milowymi i ważnymi produktami
Submit Your Opportunity
Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
A Clear Vision
Take a tour of our journey into Retinal Health through this interactive infographic or descriptive audio recording, and learn how we aim to preserve or restore vision in people with retinal diseases.
Advancing regenerative medicine
Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Contact Us
Contact our partnering team to discuss your project and learn more about how we can work together.
Collaboration Driving Innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Stem cells a new frontier
Stem cells may be a game changer for the development of new veterinary treatments. Read this story to find out why.
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Focus on Alliance Management
Stefan Walke, Global Head of Alliance Management, dzieli się swoimi spostrzeżeniami dotyczącymi zarządzania aliansami i jego wkładem w rozwój udanych i długotrwałych partnerstw.
Supply Chain Scholarship for Cowtribe
A supply chain course we sponsored boosted the career of Latifa Saaka
Aftopor®/Aftovaxpur®/Aftovax®/Aftobov®Oleosa/Aftovaxpur®Doe
FMD vaccines with highly potent and purified antigens (Aftopor®, Aftovaxpur®, Aftobov® Oleosa) allow differentiation between infected and vaccinated animals for endemic or emergency situations.
View from Both Sides of the Table
Stawiamy na zarządzanie aliansami
Antibody therapeutics business partnering PetMedix
Combining PetMedix’ expertise in veterinary biotherapeutic technology with Boehringer Ingelheim’s long experience and innovation in human antibody discovery and development provides a unique opportunity for the partners.